Skip to main content
×
Home

Seroprevalence of cytomegalovirus infection in France in 2010

  • D. ANTONA (a1), A. LEPOUTRE (a1), L. FONTENEAU (a1), C. BAUDON (a1), F. HALFTERMEYER-ZHOU (a1), Y. LE STRAT (a1) and D. LÉVY-BRUHL (a1)...
Summary
SUMMARY

Cytomegalovirus (CMV) infection remains the leading cause of congenital virus infection in developed countries. Measuring the national prevalence of this infection, especially among women of childbearing age, is of great value to estimate the risk of congenital CMV infection, as well as to identify risk groups that should be targeted for behavioural interventions and/or vaccination once a CMV vaccine finally becomes available. In order to fulfil these objectives, a seroprevalence survey was conducted in 2010, using a nationally representative, population-based sample of 2536 people aged between 15 and 49 years, living in metropolitan France and attending private microbiological laboratories for blood testing. All blood samples were analysed in the same laboratory and screened for CMV-specific IgG using an enzyme-linked immunoassay technique (Elisa PKS Medac Enzyme immunoassay). The overall point estimate of CMV infection seroprevalence for individuals aged 15–49 years was 41.9%. The estimates were higher in women than in men (respectively 45.6% and 39.3%), and people born in a non-Western country were more likely to be CMV seropositive than those born in France or in another Western country (93.7% vs. 37.7%). Our results showed that a substantial percentage of women of childbearing age in France are CMV seronegative and therefore at risk of primary CMV infection during pregnancy. Educational measures and future vaccine are key issues to prevent infection in pregnant women and congenital CMV disease.

Copyright
Corresponding author
*Author for correspondence: Dr D. Antona, Santé publique France, Saint Maurice, France. (Email: denise.antona@santepubliquefrance.fr)
References
Hide All
1. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology 2007; 17: 253276.
2. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clinical Infectious Diseases 2010; 50: 14391447.
3. Dar L, et al. Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatric Infectious Diseases Journal 2008; 27: 841843.
4. Hamprecht K, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001; 357: 513518.
5. Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore) 1985; 64: 100114.
6. Stagno S, et al. Breast milk and the risk of cytomegalovirus infection. New England Journal of Medicine 1980; 302: 10731076.
7. Pass RF, et al. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. New England Journal of Medicine 1986; 314: 14141418.
8. Marshall BC, Adler SP. The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care. American Journal of Obstetrics and Gynecology 2009; 200: 163.e1163.e5.
9. Collier AC, et al. Cytomegalovirus infection in women attending a sexually transmitted disease clinic. Journal of Infectious Diseases 1990; 162: 4651.
10. Sohn YM, et al. Cytomegalovirus infection in sexually active adolescents. Journal of Infectious Diseases 1991; 163: 460463.
11. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Reviews in Medical Virology 2007; 17: 355363.
12. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. Journal of Clinical Virology 2008; 41: 5762.
13. Fowler KB, Stagno S, Pass RF. Interval between births and risk of congenital cytomegalovirus infection. Clinical Infectious Diseases 2004; 38: 10351037.
14. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. Journal of the American Medical Association 2003; 289: 10081111.
15. Townsend CL, et al. Long term outcomes of congenital cytomegalovirus infection in Sweden and in the United Kingdom. Clinical Infectious Diseases 2013; 56: 12321239.
16. Wang C, et al. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clinical Infectious Diseases 2011; 52: e11e13.
17. Mussi-Pinhata MM, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clinical Infectious Diseases 2009; 15: 522–8.
18. de Vries JJC, et al. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Reviews in Medical Virology 2013; 23: 241–9.
19. Demmler-Harrison GJ. Congenital cytomegalovirus: public health action towards awareness, prevention, and treatment. Journal of Clinical Virology 2009; 46: S1S5.
20. Arvin AM, et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clinical Infectious Diseases 2004; 39: 233239.
21. Lepoutre A, et al. Seroprevalence of vaccine preventable diseases and of five other infectious diseases in France. Results of two national surveys, 2008–2010. Bulletin Epidémiologique Hebdomadaire 2013; 41–42: 526–34.
22. Gratacap-Cavallier B, et al. Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. European Journal of Epidemiology 1998; 14: 147152.
23. Gouarin S, et al. Congenital HCMV infection: a collaborative and comparative study of virus detection in amniotic fluid by culture and by PCR. Journal of Clinical Virology 2001; 21: 4755.
24. Lepage N, et al. Cytomegalovirus seroprevalence in exposed and unexposed populations of hospital employees. European Journal of Clinical Microbiology and Infectious Diseases 2011; 30: 6570.
25. Osborne K, Weinberg J, Miller E. The European Sero-Epidemiology Network (ESEN). Eurosurveillance 1997; 2: 9396.
26. Zou G. A modified poisson regression approach to prospective studies with binary data. American Journal of Epidemiology 2004; 159: 702706.
27. Korndewal MJ, et al. Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications. Journal of Clinical Virology 2015; 63: 5358.
28. Seale H, et al. National serosurvey of cytomegalovirus in Australia. Clinical and Vaccine Immunology 2006; 13: 11811184.
29. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Reviews in Medical Virology 2010; 20: 202213.
30. De Ory F, et al. Is there a change in cytomegalovirus seroepidemiology in Spain? European Journal of Epidemiology 2004; 19: 8589.
31. Lübeck PR, Doerr HW, Rabenau HF. Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Medical Microbiology and Immunology 2010; 199: 5360.
32. Forsgren M. Prevention of congenital and perinatal infections. Eurosurveillance 2009; 14: 24.
33. Peckham C, et al. Screening options for prevention of congenital cytomegalovirus infection. Journal of Medical Screening 2001; 8: 119–24.
34. Walker S, et al. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy and Childbirth 2013; 13: 96.
35. Schleiss MR, Plotkin SA. Cytomegalovirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 6th edn. Philadelphia: Saunders Elsevier Company, 2013, pp. 10321041.
36. American College of Obstetricians and Gynecologists. Perinatal viral and parasitic infections. ACOG Practice Bulletin 20. International Journal of Gynaecology and Obstetrics 2002; 76: 95107.
37. Vauloup-Fellous C, et al. Does hygiene counselling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. Journal of Clinical Virology 2009; 46(Suppl. 4): S49S53.
38. Haute autorité de santé (French National Agency for Accreditation and Evaluation in Healthcare). Assessment of screening for cytomegalovirus (CMV) infection in pregnant women in France, 2004. ( http://www.has-sante.fr/portail/upload/docs/application/pdf/cytomegalovirus_abstract.pdf). Accessed 2 September 2016.
39. McVoy MA. Cytomegalovirus vaccines. Clinical Infectious Diseases 2013; 57(Suppl.4): S196S199.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 5
Total number of PDF views: 71 *
Loading metrics...

Abstract views

Total abstract views: 472 *
Loading metrics...

* Views captured on Cambridge Core between 7th February 2017 - 23rd November 2017. This data will be updated every 24 hours.